ClinicalTrials.gg

Program

enlicitide chloride

Also written as “Enlicitide Chloride” and “[¹⁴C]Enlicitide chloride”.

Its studies are mostly in Hypercholesterolemia, led by Merck.

Furthest: phase 1, since Oct 1, 20214 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck40 open or runningphase 1since Oct 1, 2021Oct 1, 2021none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 1, 2021First study: phase 1 study in Moderate Renal ImpairmentFirst studyNCT05070390 · 18 enrolled · United States
  2. Oct 21, 20242 phase 1 studiesNCT06655311, NCT06658626
  3. Feb 3, 2025Phase 1 study in HealthyNCT06814106 · 37 enrolled · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06814106Healthy · China1CompletedMay 8, 202337
NCT06658626Healthy · United States1CompletedAug 2, 20238
NCT06655311Hypercholesterolemia · United States1CompletedJan 2, 202456
NCT05070390Moderate Renal Impairment · United States1CompletedMay 3, 202318

How it is read

Names in the registry

  • “Enlicitide Chloride”, 3 entries
  • “[¹⁴C]Enlicitide chloride”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.